Akebia Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Net Income	-43.03	-51.93	-94.23	-282.02	-384.84	-279.66	Upgrade
Depreciation & Amortization	43.41	41.85	35.28	36.13	32.66	36.42	Upgrade
Share-Based Compensation	9.19	9.32	17.85	22.74	24.46	11.93	Upgrade
Other Operating Activities	-34.84	-22.62	-32.06	-29.8	217.34	-26.12	Upgrade
Operating Cash Flow	-25.28	-23.38	-73.15	-252.97	-110.39	-257.44	Upgrade
Capital Expenditures	0	0	-0.11	-0.06	-0.32	-6.66	Upgrade
Change in Investments	0	0	0	40	-39.69	217.83	Upgrade
Investing Cash Flow	0	0	-0.11	39.94	-40	211.18	Upgrade
Share Issuance / Repurchase	25.71	6.79	7.6	88.95	211.75	26.3	Upgrade
Debt Issued / Paid	-15.73	-32	-33	0	19.98	62.67	Upgrade
Other Financing Activities	-0.75	-	40	44.78	-	-	Upgrade
Financing Cash Flow	9.24	-25.21	14.6	133.73	231.72	88.97	Upgrade
Net Cash Flow	-16.04	-48.59	-58.67	-79.29	81.33	42.71	Upgrade
Free Cash Flow	-25.28	-23.38	-73.27	-253.02	-110.71	-264.1	Upgrade
Free Cash Flow Margin	-13.50%	-12.02%	-25.05%	-119.55%	-37.57%	-78.83%	Upgrade
Free Cash Flow Per Share	-0.12	-0.13	-0.40	-1.52	-0.80	-2.23	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).